Authors: De Gruttola, VG Clax, P DeMets, DL Downing, GJ Ellenberg, SS Friedman, L Gail, MH Prentice, R Wittes, J Zeger, SL

Citation: Vg. De Gruttola et al., Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop, CONTR CL TR, 22(5), 2001, pp. 485-502

Authors: Atkinson, AJ Colburn, WA DeGruttola, VG DeMets, DL Downing, GJ Hoth, DF Oates, JA Peck, CC Schooley, RT Spilker, BA Woodcock, J Zeger, SL

Citation: Aj. Atkinson et al., Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework, CLIN PHARM, 69(3), 2001, pp. 89-95

Authors: Zolyomi, A Zhao, XH Downing, GJ Balla, T

Citation: A. Zolyomi et al., Localization of two distinct type III phosphatidylinositol 4-kinase enzymemRNAs in the rat, AM J P-CELL, 278(5), 2000, pp. C914-C920